| Bioactivity | Brentuximab vedotin (cAC10-vcMMAE) is an antibody-drug conjugate (ADC) comprising an anti-CD30 antibody and the cytotoxic agent Monomethyl auristatin E (MMAE). Brentuximab vedotin inhibits CD30-positive cells with an IC50 of 2.5 ng/mL. Brentuximab vedotin can be used for the research of relapsed and refractory Hodgkin lymphoma[1][2]. |
| Invitro | Brentuximab vedotin (cAC10-vcMMAE) (1 μg/mL; 96 h) shows cytotoxicity to CD30+ in Karpas 299 cells[2].Brentuximab vedotin (CAC10-VCMMAE) (1 μg/mL; 12, 24 and 48 h) selectively induces growth arrest in G2/M phase then lead to apoptotic cell death[2]. Cell Cytotoxicity Assay[2] Cell Line: |
| Name | Brentuximab vedotin |
| CAS | 914088-09-8 |
| Storage | Please store the product under the recommended conditions in the Certificate of Analysis. |